New study tests drug combo to fight liver cancer linked to hepatitis b
NCT ID NCT07253220
Summary
This study aims to find out if using two antiviral drugs together works better than using one drug alone for people with advanced liver cancer caused by hepatitis B. Researchers will compare how long 120 patients live after starting cancer immunotherapy, depending on which antiviral treatment they receive. The goal is to see if the combination therapy improves survival by better controlling the underlying hepatitis B virus.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.